Group 1 - BofA Securities analyst Allen Lutz reiterated a Buy rating on Cardinal Health, Inc. and raised the price forecast from $165 to $170, anticipating strong performance and favorable industry dynamics [1][2] - Cardinal Health is set to host an investor day on June 12, where it will provide an updated business outlook and a roadmap for sustained double-digit EPS growth [1][2] - The company is expected to revise its Pharmaceutical and Specialty Solutions EBIT growth outlook upward, with long-term Pharmaceutical EBIT growth targets potentially increasing from 4-6% to 5-7% or 5-8% [2][3] Group 2 - Cardinal Health's prior scale disadvantage in specialty areas is diminishing, and recent M&A activity could have a more significant growth impact compared to larger competitors [6] - The company plans to update its growth path for the Global Medical Products and Distribution segment, addressing tariff impacts and evolving demand trends [7] - The Other segment has shown solid growth, with potential for sustained high-single-digit EBIT growth, while maintaining a balanced capital allocation strategy [8]